STEMI-Lipids Study

Design, Study Procedures and Eligibility
This clinical trial is a prospective, observational study of lipid levels and inflammatory markers immediately after an ST-elevation myocardial infarction, changes in the following days and after 3 months.
Collection of blood samples take place at day 1 (admission, before the PCI), day 2 (in the morning) and day 3 (in the morning), as well as during a 3-month follow up visit.

Dataset / Parameters
The following parameters will be documented for all 85 STEMI patients that signed the informed consent form: Initials, gender, age and birth date, concomitant diseases and medications, lipid-therapies, medical history of cardio-vascular events, as well as lipid-parameters and inflammatory factors listed below.

Lipid Factors		Inflammatory Factors
Lipoprotein-a	Chylomicrons	hsCRP
LDL-Cholesterol (LDL-C)	Apolipoprotein B	IL1/IL-1ß
LDL-Subfractions	Apolipoprtein A1	IL-6
HDL-Cholesterol	Total Triglyceride (TG)	TNFα
HDL-Subfractions	PCSK9	ROS
Non-HDL	oxLDL-C	
VLDL	CETP	
IDL	HMG-CoA	

Table 1: *Key Lipid- and Inflammatory Factors*

Samples / Material
Starting in Oct. 2019, samples from 85 subjects will be collected.

Principal Investigator:
Univ.-Prof. Dr.med.univ. Robert Zweiker
Medical University of Graz
Department of Internal Medicine, Division of Cardiology
Auenbruggerplatz 15

Co-Investigator:
Assoc.Prof. Dr. Harald Sourij
Department of Internal Medicine, Division of Endocrinology and Diabetology
Auenbruggerplatz 15, 8036 Graz

Contact:
biobank-pm@medunigraz.at
robert.zweiker@medunigraz.at
ha.sourij@medunigraz.at

Medical University of Graz | Biobank